[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[S. 1322 Introduced in Senate (IS)]

113th CONGRESS
  1st Session
                                S. 1322

To amend the Controlled Substances Act relating to controlled substance 
                               analogues.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 18, 2013

Ms. Klobuchar (for herself, Mr. Graham, and Mrs. Feinstein) introduced 
the following bill; which was read twice and referred to the Committee 
                            on the Judiciary

_______________________________________________________________________

                                 A BILL


 
To amend the Controlled Substances Act relating to controlled substance 
                               analogues.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Synthetic Abuse and Labeling of 
Toxic Substances Act of 2013'' or the ``SALTS Act''.

SEC. 2. CONTROLLED SUBSTANCE ANALOGUES.

    Section 203 of the Controlled Substances Act (21 U.S.C. 813) is 
amended--
            (1) by striking ``A controlled'' and inserting ``(a) In 
        General.--A controlled''; and
            (2) by adding at the end the following:
    ``(b) Determination.--In determining whether a controlled substance 
analogue was intended for human consumption under subsection (a), the 
following factors may be considered, along with any other relevant 
factors:
            ``(1) The marketing, advertising, and labeling of the 
        substance.
            ``(2) The known efficacy or usefulness of the substance for 
        the marketed, advertised or labeled purpose.
            ``(3) The difference between the price at which the 
        substance is sold and the price at which the substance it is 
        purported to be or advertised as is normally sold.
            ``(4) The diversion of the substance from legitimate 
        channels and the clandestine importation, manufacture, or 
        distribution of the substance.
            ``(5) Whether the defendant knew or should have known the 
        substance was intended to be consumed by injection, inhalation, 
        ingestion, or any other immediate means.
    ``(c) Limitation.--For purposes of this section, evidence that a 
substance was not marketed, advertised, or labeled for human 
consumption, by itself, shall not be sufficient to establish that the 
substance was not intended for human consumption.''.
                                 <all>